BACKGROUND: Pre-clinical data have suggested a therapeutic role of Hedgehog (Hh) pathway inhibitors in chondrosarcoma. METHODS: This phase II trial included patients with progressive advanced chondrosarcoma. They received GDC-0449 150 mg/day (days 1-28, 28-day cycle). The primary end point was the 6-month clinical benefit rate (CBR) defined as the proportion of patients with non-progressive disease at 6 months. A 6-month CBR of 40% was considered as a reasonable objective to claim drug efficacy. RESULTS: Between February 2011 and February 2012, 45 patients were included. Twenty had received prior chemotherapy. Thirty-nine were assessable for efficacy. The 6-month CBR was 25.6% (95% confidence interval 13.0-42.1). All stable patients had grade 1 or 2 conventional chondrosarcoma with documented progression within the 6 months before inclusion. All but one with available data also had overexpression of the Hh ligand. Median progression-free and overall survivals were 3.5 and 12.4 months, respectively. The most frequent adverse events were grade 1 or 2 myalgia, dysgeusia and alopecia. CONCLUSIONS: GDC-0449 did not meet the primary end point of this trial. Results suggest some activity in a subset of patients with progressive grade 1 or 2 conventional chondrosarcoma. Further studies assessing its role in combination with chemotherapy are warranted. CLINICALTRIALSGOV IDENTIFIER: NCT01267955.
BACKGROUND: Pre-clinical data have suggested a therapeutic role of Hedgehog (Hh) pathway inhibitors in chondrosarcoma. METHODS: This phase II trial included patients with progressive advanced chondrosarcoma. They received GDC-0449 150 mg/day (days 1-28, 28-day cycle). The primary end point was the 6-month clinical benefit rate (CBR) defined as the proportion of patients with non-progressive disease at 6 months. A 6-month CBR of 40% was considered as a reasonable objective to claim drug efficacy. RESULTS: Between February 2011 and February 2012, 45 patients were included. Twenty had received prior chemotherapy. Thirty-nine were assessable for efficacy. The 6-month CBR was 25.6% (95% confidence interval 13.0-42.1). All stable patients had grade 1 or 2 conventional chondrosarcoma with documented progression within the 6 months before inclusion. All but one with available data also had overexpression of the Hh ligand. Median progression-free and overall survivals were 3.5 and 12.4 months, respectively. The most frequent adverse events were grade 1 or 2 myalgia, dysgeusia and alopecia. CONCLUSIONS: GDC-0449 did not meet the primary end point of this trial. Results suggest some activity in a subset of patients with progressive grade 1 or 2 conventional chondrosarcoma. Further studies assessing its role in combination with chemotherapy are warranted. CLINICALTRIALSGOV IDENTIFIER: NCT01267955.
Authors: J G van Oosterwijk; B Herpers; D Meijer; I H Briaire-de Bruijn; A M Cleton-Jansen; H Gelderblom; B van de Water; J V M G Bovée Journal: Ann Oncol Date: 2011-11-23 Impact factor: 32.976
Authors: J Xie; M Murone; S M Luoh; A Ryan; Q Gu; C Zhang; J M Bonifas; C W Lam; M Hynes; A Goddard; A Rosenthal; E H Epstein; F J de Sauvage Journal: Nature Date: 1998-01-01 Impact factor: 49.962
Authors: A Italiano; O Mir; A Cioffi; E Palmerini; S Piperno-Neumann; C Perrin; L Chaigneau; N Penel; F Duffaud; J E Kurtz; O Collard; F Bertucci; E Bompas; A Le Cesne; R G Maki; I Ray Coquard; J Y Blay Journal: Ann Oncol Date: 2013-10-07 Impact factor: 32.976
Authors: N Penel; G D Demetri; J Y Blay; S Cousin; R G Maki; S P Chawla; I Judson; M von Mehren; P Schöffski; J Verweij; P Casali; S Rodenhuis; H J Schütte; A Cassar; J Gomez; A Nieto; P Zintl; M J Pontes; A Le Cesne Journal: Ann Oncol Date: 2012-11-01 Impact factor: 32.976
Authors: Angela Ylenia Giuffrida; Jorge E Burgueno; Leonidas G Koniaris; Juan C Gutierrez; Robert Duncan; Sean P Scully Journal: J Bone Joint Surg Am Date: 2009-05 Impact factor: 5.284
Authors: A Italiano; O Mir; A Cioffi; E Palmerini; S Piperno-Neumann; C Perrin; L Chaigneau; N Penel; F Duffaud; J E Kurtz; O Collard; F Bertucci; E Bompas; A Le Cesne; R G Maki; I Ray Coquard; J Y Blay Journal: Ann Oncol Date: 2013-10-07 Impact factor: 32.976
Authors: William D Tap; Victor M Villalobos; Gregory M Cote; Howard Burris; Filip Janku; Olivier Mir; Murali Beeram; Andrew J Wagner; Liewen Jiang; Bin Wu; Sung Choe; Katharine Yen; Camelia Gliser; Bin Fan; Sam Agresta; Shuchi S Pandya; Jonathan C Trent Journal: J Clin Oncol Date: 2020-03-24 Impact factor: 44.544
Authors: Hussein A Tawbi; Melissa Burgess; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; James Hu; Sandra D'Angelo; Steven Attia; Richard F Riedel; Dennis A Priebat; Sujana Movva; Lara E Davis; Scott H Okuno; Damon R Reed; John Crowley; Lisa H Butterfield; Ruth Salazar; Jaime Rodriguez-Canales; Alexander J Lazar; Ignacio I Wistuba; Laurence H Baker; Robert G Maki; Denise Reinke; Shreyaskumar Patel Journal: Lancet Oncol Date: 2017-10-04 Impact factor: 41.316
Authors: Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639